Two modern office buildings.
Advertisement
04/05/2021

Amneal acquires Kashiv Specialty Pharmaceuticals

Through the acquisition of Kashiv Specialty Pharmaceuticals, Amneal has gained a pipeline of 505(b)2 branded products and complex generics.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Amneal has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.

“We are very pleased to announce the completion of this transaction. Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics. Perhaps most importantly, we are adding a team of world class R&D scientists with a proven track record of developing complex generic products (e.g. Yuvafem and EluRyng), as well as a platform of innovative drug delivery technologies. This transaction is just the latest step in making Amneal 2.0 a reality,” said Chirag and Chintu Patel, co-CEOs.

 

Advertisement
Advertisement